Rick Pearson is an activist investor focused on U.S. listed stocks in the U.S. and in China. He was previously an investment banker in one of Wall Street's largest investment banks for nearly a decade, stationed between New York, Hong Kong and London. As a director in equity capital markets he oversaw over $30 billion in equity and equity linked transactions, primarily for health care and technology companies.
Pearson spends his time living between Los Angeles and Beijing. He has a degree in finance from the University of Southern California and has studied Mandarin since 1991.
Recent Articles By The Author
Antibiotic for Treatment of Superbugs Could Send Cempra Shares Soaring
Solithera is well along in the FDA approval process, and if the antibiotic is approved, the North Carolina-based company will have a potential blockbuster drug.
4 Reasons Why TrueCar's Stock Is Poised to Re-accelerate
The stock has been punished too severely. Here's why it should bounce back.
Papa Murphy's Investors Should Flee Kitchen Before They Get Burned
Papa Murphy's shares have had a good run so far this year. Here's why it won't last.
3 Oncology Biotechs to Watch
Handicapping the potential of Galena Biopharma, CytRx and Northwest Biotherapeutics requires a solid understanding of what has been driving share prices.
Best Trade for Renewable Energy Is Short
Though Renewable Energy's Tuesday's acquisition of Syntroleum is puzzling, it is easy to see why REGI, PLUG and other new energy stocks could be set for sharp drops.
Napco, Lionbridge: 2 Small-Caps Making Big Moves
Some of the best investment calls in 2013 have been among small-mid cap tech and healthcare stocks trading for $5-$10 with medium-term catalysts.
A Closer Look at Quest Diagnostics, Lab Corp and Hologic
Obamacare may not these diagnostic stocks higher, but it is likely to give them meaningful boosts in revenue.
Watch for a Big Short Squeeze in Cleantech Solutions
With short interest rising and the potential for a strong earnings announcement, CleanTech could soon re-test its high for the year of around $11.
Biozone: A Little Biotech Setting Up for Big Gains
Biozone is very likely to look like a no-brainer by year-end.
Beware the Chinese Rumor Mill
Watch out for the companies that reverse-split to avoid delisting and then are the subject of explosive rumors. They are rife for manipulation.